Recruiting NCT06462664
Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Myeloproliferative Neoplasm. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Exploring the Impact of Monocytes in Myeloproliferative Neoplasia
Overview
Impact of monocytes on Myeloproliferative Neoplasm hematopoietic stem cell growth and differentiation in vitro
Primary outcome measures
- Proliferation and differentiation of hematopoitic stem/progenitor cells [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Diagnosis of MPN in the participating center
- Over 18 yo
Exclusion criteria
- Not able to consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-only
Study locations
France · 1 center
- Chu Brest — Brest
Identifiers
NCT: NCT06462664 · 29BRC24.0134 - EMYNEM